摘要
目的探讨不同剂量的丙种球蛋白治疗新生儿ABO溶血病的临床疗效。方法选取我院自2013年8月至2015年6月收治的150例新生儿ABO溶血病患儿作为研究对象,将其按照入院顺序均分为A、B、C 3组,A组患者给予1g/kg的丙种球蛋白进行治疗,B组给予0.5g/kg的丙种球蛋白进行治疗,C组不给丙种球蛋白,只进行常规的治疗,对比3组新生儿治疗后的临床疗效。结果 3组患儿治疗前的总胆红素水平、红细胞计数、血红蛋白含量及黄疸出现时间均差异无统计学意义(P>0.05);治疗后,A、B组患儿总胆红素水平、红细胞计数、血红蛋白含量及黄疸消退时间均优于C组,差异具有统计学意义(P<0.05);同时,A组患儿的总胆红素水平、红细胞计数、血红蛋白含量及黄疸消退时间均优于B组,差异具有统计学意义(P<0.05)。结论丙种球蛋白治疗新生儿ABO溶血病具有很好的临床疗效,尤其是大剂量的丙种球蛋白疗效显著,值得临床上推广应用。
Objective To discuss investigate the curative effect of different dose of intravenous immunoglob- ulin in on the newborn with ABO hemolytic disease. Methods One hundred and fifty cases with newborn ABO he- molytic disease, which who were admitted in our hospital during August 2013 June 2015, were selected as the re- search objects and divided into the A group, B group and the C group randomly. A group was given intravenous immunoglobulin treatment with 1 g/kg, B group was given intravenous immunoglobulin treatment with 0.5 g/kg, and the C group was not given intravenous immunoglobulin treatment, only routine treatment. The clinical cura- tive effects of newborn after treatment of the three groups were compared. Results Total bilirubin level, red blood cell count, hemoglobin content and jaundice fade time before the treatment of the three groups was were of no sta- tistically significant difference （ P 〉0.05）. After treatment, total bilirubin level, red blood cell count, hemoglo- bin content and jaundice fadefade time of the A group and B group were better than that those of C group, the difference was significant statistically significant （ P 〈0.05）. At the same time, total bilirubin level, red blood cell count, hemoglobin content and jaundice fade fade time of the A group were better than that those of B group, the difference was significant statistically significant （ P 〈0.05）. Conclusion Intravenous immunoglobulin treat- ment for newborn ABO hemolytic disease has good clinical efficacy, especially the curative effect of large dose of intravenous immunoglobulin curative effect is distinct, worthy of clinical application.
出处
《山西医药杂志》
CAS
2016年第4期383-385,共3页
Shanxi Medical Journal
基金
四川省卫生厅科技攻关计划(120113)
